GGrantIndex
← Search

Community Outreach and Engagement

$149,131P30FY2025CANIH

University Of Pittsburgh At Pittsburgh, Pittsburgh PA

Investigators

Linked publications & trials

Abstract

Abstract: Community Outreach and Engagement UPMC Hillman Cancer Center (HCC) works throughout western Pennsylvania to assess the cancer burden and address, through community engagement and high-quality research, the cancer incidence and mortality in its catchment area (CA). The HCC CA consists of 25 rural and 4 urban counties located in Appalachia. The counties collectively are largely low income with higher than U.S. rates for age-adjusted cancer incidence (breast, prostate, colorectal, lung, thyroid) and mortality (breast, prostate, and lung), with population variability noted in Allegheny County for lung, breast, and colorectal cancer mortality. CA risk behaviors include lower than national rates of cancer screening and high rates of obesity and tobacco usage. Under the leadership of Dr. Natacha De Genna, the HCC’s Committee for Community Outreach & Engagement (CCOE) uses several data sources and strategies to define cancer incidence, mortality, screening behaviors, burdens, and risks. Using these data, CCOE, in close collaboration with the HCC research programs and the Community Advisory Board and partners, directs the development and implementation of HCC CA initiatives and evaluation of these efforts toward cancer burden reduction. These initiatives include a research portfolio with contributions from each HCC program directed at identified CA burdens, and provision of evidence-based community engagement to meet identified education, screening and support needs of CA populations. These efforts include the successful navigation of patients to cancer screening and, if necessary, through treatment. HCC’s program of CA research includes several initiatives focused on developing new agents directed at specific CA high incidence and mortality malignancies; tobacco cessation; and better understanding and mitigation of population variability in cancer treatment. Research also includes the long-standing Pittsburgh Lung Screening Study (PLuSS), now used for developing risk biomarkers; identification of regionally unique cancer threats and resilience; and several initiatives, including novel delivery systems in rural areas and improving recruitment to clinical trials.

View original record on NIH RePORTER →